Telemedicine Program in Type 1 Diabetes and CSII
Diabetes Mellitus, Type 1
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Type 1 diabetes, Health technologies, Continuous subcutaneous insulin infusion, Telemedicine, Glycemic variability, Inflammatory markers,, Oxidative stress, Depression, Quality of life, Cost-effectiveness
Eligibility Criteria
Inclusion Criteria:
- Type 1 diabetes over 2 years of development with C plasma levels <0.5 ng / ml, and ISCI treated for> 6 months peptide.
- Age between 16 and 65 years (inclusive).
- HbA1c <10%.
- Absence of concomitant drug therapy that could affect blood glucose levels.
- Absence of chronic renal failure, abnormal liver function tests, thyroid disease active (except properly replaced hypothyroidism).
- Absence of acute decompensation Ketotic at baseline.
Exclusion Criteria:
- type 2 diabetes.
- type 1 diabetes treated with multiple daily insulin injections.
- Women pregnant or planning pregnancy.
- severe macrovascular or microvascular complications
- disabling psychological disorders.
- No collaboration (not signed informed consent).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Other
Other
Other
Other
Group 1a. Control
Group 2a. Telemedicine program
Group 1b. Telemedicine program
Group 2b. Control
Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).